Patient Characteristics and Outcomes of Type 2 Myocardial Infarction During Heart Failure Hospitalizations in the United States.
Aged
Anemia
/ epidemiology
Case-Control Studies
Comorbidity
Female
Heart Failure
/ complications
Hospital Costs
Hospital Mortality
Hospitalization
/ economics
Humans
Hypertension
/ epidemiology
Length of Stay
/ economics
Male
Myocardial Infarction
/ complications
Nervous System Diseases
/ epidemiology
Nursing Homes
Patient Discharge
/ statistics & numerical data
Patient Readmission
/ statistics & numerical data
Prevalence
Renal Insufficiency, Chronic
/ epidemiology
Sex Factors
United States
/ epidemiology
Weight Loss
Heart failure
Outcomes research
Readmissions
Type 2 myocardial infarction
Journal
The American journal of medicine
ISSN: 1555-7162
Titre abrégé: Am J Med
Pays: United States
ID NLM: 0267200
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
04
05
2021
revised:
14
05
2021
accepted:
19
05
2021
pubmed:
3
7
2021
medline:
15
12
2021
entrez:
2
7
2021
Statut:
ppublish
Résumé
Type 2 myocardial infarction (MI) is increasingly diagnosed in patients with heart failure (HF). A paucity of data exists pertinent to the contemporary prevalence and impact of type 2 MI in patients with HF. We studied the patient profiles and the prognostic impact of type 2 MI on outcomes of HF hospitalizations. The Nationwide Readmission Database 2018 was queried for patients with HF hospitalizations with and without type 2 MI. Baseline characteristics, inpatient outcomes, and 30-day all-cause readmissions between both cohorts were compared. Of 1,072,674 primary HF hospitalizations included in the study, 28,813 (2.7%) had type 2 MI. Patients with type 2 MI were more likely to be males (56.5% vs 51.6%; P < .001) and had a higher prevalence of hypertension (94% vs 92.2%; P < .001), prior myocardial infarction (17.1% vs 14.9%; P < .001), anemia (9.1% vs 8.1%; P < .001), chronic kidney disease (55.7% vs 49.4%; P < .001), neurological disorders (9.4% vs 7.3%; P < .001), and weight loss (7.3% vs 5.6%; P < .001). Compared with their counterparts without type 2 MI, patients with HF with type 2 MI had significantly higher in-hospital mortality (adjusted odds ratio [aOR], 1.53; 95% confidence interval [CI], 1.37-1.72), hospital costs (adjusted parameter estimate, $1785; 95% CI, 1388-2182), discharge to nursing facility (aOR, 1.22; 95% CI, 1.15-1.29), longer length of stay (adjusted parameter estimate, 0.53; 95% CI, 0.42-0.64), and rate of 30-day all-cause readmissions (aOR, 1.06; 95% CI, 1.01-1.12). Type 2 MI in patients hospitalized with HF is associated with higher mortality and resource utilization in the United States.
Sections du résumé
BACKGROUND
Type 2 myocardial infarction (MI) is increasingly diagnosed in patients with heart failure (HF). A paucity of data exists pertinent to the contemporary prevalence and impact of type 2 MI in patients with HF. We studied the patient profiles and the prognostic impact of type 2 MI on outcomes of HF hospitalizations.
METHODS
The Nationwide Readmission Database 2018 was queried for patients with HF hospitalizations with and without type 2 MI. Baseline characteristics, inpatient outcomes, and 30-day all-cause readmissions between both cohorts were compared.
RESULTS
Of 1,072,674 primary HF hospitalizations included in the study, 28,813 (2.7%) had type 2 MI. Patients with type 2 MI were more likely to be males (56.5% vs 51.6%; P < .001) and had a higher prevalence of hypertension (94% vs 92.2%; P < .001), prior myocardial infarction (17.1% vs 14.9%; P < .001), anemia (9.1% vs 8.1%; P < .001), chronic kidney disease (55.7% vs 49.4%; P < .001), neurological disorders (9.4% vs 7.3%; P < .001), and weight loss (7.3% vs 5.6%; P < .001). Compared with their counterparts without type 2 MI, patients with HF with type 2 MI had significantly higher in-hospital mortality (adjusted odds ratio [aOR], 1.53; 95% confidence interval [CI], 1.37-1.72), hospital costs (adjusted parameter estimate, $1785; 95% CI, 1388-2182), discharge to nursing facility (aOR, 1.22; 95% CI, 1.15-1.29), longer length of stay (adjusted parameter estimate, 0.53; 95% CI, 0.42-0.64), and rate of 30-day all-cause readmissions (aOR, 1.06; 95% CI, 1.01-1.12).
CONCLUSION
Type 2 MI in patients hospitalized with HF is associated with higher mortality and resource utilization in the United States.
Identifiants
pubmed: 34214459
pii: S0002-9343(21)00398-3
doi: 10.1016/j.amjmed.2021.05.022
pmc: PMC9131468
mid: NIHMS1804048
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1371-1379.e2Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL139430
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
JAMA Cardiol. 2021 Aug 1;6(8):952-956
pubmed: 33566058
Circulation. 2019 Nov 12;140(20):1661-1678
pubmed: 31416350
J Am Heart Assoc. 2017 Nov 29;6(12):
pubmed: 29187385
Ann Transl Med. 2018 Aug;6(15):298
pubmed: 30211186
Am J Cardiol. 2017 Mar 1;119(5):760-769
pubmed: 28109560
JACC Heart Fail. 2017 Aug;5(8):578-588
pubmed: 28501521
JACC Heart Fail. 2018 May;6(5):388-397
pubmed: 29655830
J Am Coll Cardiol. 2019 Apr 16;73(14):1846-1860
pubmed: 30975302
J Am Coll Cardiol. 2018 Sep 4;72(10):1166-1170
pubmed: 30165988
J Am Heart Assoc. 2018 Mar 26;7(7):
pubmed: 29581221
Circ Heart Fail. 2018 Dec;11(12):e004873
pubmed: 30562099
Cardiovasc Revasc Med. 2022 Feb;35:185-186
pubmed: 33714698
Am J Cardiol. 2015 Aug 1;116(3):400-5
pubmed: 26037295
JAMA Cardiol. 2019 May 1;4(5):460-464
pubmed: 30879022
J Am Coll Cardiol. 2019 Mar 12;73(9):1004-1012
pubmed: 30846093
Eur J Heart Fail. 2009 Feb;11(2):170-7
pubmed: 19168515
Circulation. 2018 Jul 3;138(1):12-24
pubmed: 29519849
N Engl J Med. 2008 May 15;358(20):2117-26
pubmed: 18480204
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Circ Cardiovasc Qual Outcomes. 2021 Jan;14(1):e007440
pubmed: 33161772
Am J Cardiol. 2017 Oct 1;120(7):1070-1076
pubmed: 28781023
QJM. 2011 Aug;104(8):639-51
pubmed: 21558329
Am J Cardiol. 2021 May 15;147:8-15
pubmed: 33621523
Am Heart J. 2019 Jul;213:18-29
pubmed: 31078113
Eur Heart J. 2008 Nov;29(21):2641-50
pubmed: 18819960
J Am Coll Cardiol. 2021 Feb 23;77(7):848-857
pubmed: 33602466
Circulation. 2014 Sep 16;130(12):966-75
pubmed: 25135276
Circulation. 2018 Mar 20;137(12):1236-1245
pubmed: 29150426
Am Heart J. 2008 Feb;155(2):200-7
pubmed: 18215587
Circ Heart Fail. 2011 May;4(3):293-300
pubmed: 21447803
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
Circ Res. 2020 Mar 13;126(6):750-764
pubmed: 31969053
JACC Heart Fail. 2019 Feb;7(2):87-97
pubmed: 30553904
J Am Coll Cardiol. 2017 Jun 27;69(25):3042-3051
pubmed: 28641794
Int J Cardiol. 2018 Sep 1;266:174-179
pubmed: 29887443
JAMA. 2018 Dec 25;320(24):2542-2552
pubmed: 30575880
Circ Heart Fail. 2011 May;4(3):301-7
pubmed: 21467294
J Am Heart Assoc. 2020 May 18;9(10):e015978
pubmed: 32384008
BMJ. 2020 Jan 15;368:l6831
pubmed: 31941686